Bone Biologics Corp Total Assets
Bone Biologics Corp total assets. Based on the latest financial reports, Bone Biologics Corp (BBLG) holds total assets worth $4.44 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Bone Biologics Corp for the company's overall valuation and market capitalisation.
Total Assets of Bone Biologics Corp (2009–2025)
Total assets of Bone Biologics Corp from 2009 to 2025. This chart illustrates how Bone Biologics Corp's total assets have evolved over time, based on quarterly financial data. See Bone Biologics Corp (BBLG) stock price for real-time trading data and today's change.
Bone Biologics Corp - Asset Composition Analysis
Bone Biologics Corp Total Assets Breakdown (December 2025)
Bone Biologics Corp total assets breakdown as of December 2025. Bone Biologics Corp's total assets of $4.44 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.0% |
| Accounts Receivable | $9.89K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Bone Biologics Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Bone Biologics Corp (BBLG) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bone Biologics Corp's current assets represent 100.0% of total assets in 2025, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 92.0% of total assets in 2025, up from 0.0% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Bone Biologics Corp Competitors by Total Assets
Key competitors of Bone Biologics Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Bone Biologics Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.67 | 17.24 | 0.00 |
| Quick Ratio | 8.67 | 17.24 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.92 Million | $6.60 Million | $-15.13 Million |
Bone Biologics Corp - Advanced Valuation Insights
This section examines the relationship between Bone Biologics Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.36 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 50.1% |
| Total Assets | $5.80 Million |
| Market Capitalization | $974.27K USD |
Valuation Analysis
Below Book Valuation: The market values Bone Biologics Corp's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Bone Biologics Corp's assets grew by 50.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bone Biologics Corp (2009–2025)
The table below shows the annual total assets of Bone Biologics Corp from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.80 Million | +50.11% |
| 2024-12-31 | $3.86 Million | +3.31% |
| 2023-12-31 | $3.74 Million | -56.00% |
| 2022-12-31 | $8.50 Million | +27.26% |
| 2021-12-31 | $6.68 Million | -- |
| 2020-12-31 | $0.00 | -- |
| 2019-12-31 | $30.83K | -97.04% |
| 2018-12-31 | $1.04 Million | +30.80% |
| 2017-12-31 | $795.66K | -18.23% |
| 2016-12-31 | $973.09K | -53.22% |
| 2015-12-31 | $2.08 Million | -45.56% |
| 2014-12-31 | $3.82 Million | +4277.06% |
| 2013-12-31 | $87.31K | +3683655.27% |
| 2012-12-31 | $2.37 | -100.01% |
| 2009-12-31 | $-39.77K | -- |
About Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, a… Read more